Skip to Content
Merck
CN
  • Bile acids repress hypoxia-inducible factor 1 signaling and modulate the airway immune response.

Bile acids repress hypoxia-inducible factor 1 signaling and modulate the airway immune response.

Infection and immunity (2014-06-11)
Claire Legendre, F Jerry Reen, David F Woods, Marlies J Mooij, Claire Adams, Fergal O'Gara
ABSTRACT

Gastroesophageal reflux (GER) frequently occurs in patients with respiratory disease and is particularly prevalent in patients with cystic fibrosis. GER is a condition in which the duodenogastric contents of the stomach leak into the esophagus, in many cases resulting in aspiration into the respiratory tract. As such, the presence of GER-derived bile acids (BAs) has been confirmed in the bronchoalveolar lavage fluid and sputum of affected patients. We have recently shown that bile causes cystic fibrosis-associated bacterial pathogens to adopt a chronic lifestyle and may constitute a major host trigger underlying respiratory infection. The current study shows that BAs elicit a specific response in humans in which they repress hypoxia-inducible factor 1α (HIF-1α) protein, an emerging master regulator in response to infection and inflammation. HIF-1α repression was shown to occur through the 26S proteasome machinery via the prolyl hydroxylase domain (PHD) pathway. Further analysis of the downstream inflammatory response showed that HIF-1α repression by BAs can significantly modulate the immune response of airway epithelial cells, correlating with a decrease in interleukin-8 (IL-8) production, while IL-6 production was strongly increased. Importantly, the effects of BAs on cytokine production can also be more dominant than the bacterium-mediated effects. However, the effect of BAs on cytokine levels cannot be fully explained by their ability to repress HIF-1α, which is not surprising, given the complexity of the immune regulatory network. The suppression of HIF-1 signaling by bile acids may have a significant influence on the progression and outcome of respiratory disease, and the molecular mechanism underpinning this response warrants further investigation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium taurodeoxycholate hydrate, ≥95% (HPLC)
Sigma-Aldrich
Sodium glycodeoxycholate, BioXtra, ≥97% (HPLC)
Sigma-Aldrich
Chenodeoxycholic acid
Sigma-Aldrich
Cholic acid, from bovine and/or ovine, ≥98%
Chenodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
Cholic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Cholic acid, Vetec, reagent grade, 98%
Sigma-Aldrich
L-Glutamine
Supelco
L-Glutamine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Glutamine, BioUltra, ≥99.5% (NT)
SAFC
L-Glutamine
Sigma-Aldrich
Deoxycholic acid, ≥99.0% (T)
Sigma-Aldrich
L-Glutamine, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-Glutamine, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Sodium cholate hydrate, BioReagent, suitable for cell culture
Sigma-Aldrich
Deoxycholic acid, ≥98% (HPLC)
Sigma-Aldrich
Sodium chenodeoxycholate, ≥97%
Sigma-Aldrich
Sodium glycochenodeoxycholate
Sigma-Aldrich
Sodium glycocholate hydrate, ≥95% (TLC)
Sigma-Aldrich
Sodium deoxycholate, ≥97% (titration)
Sigma-Aldrich
L-Glutamine, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Sodium taurochenodeoxycholate
Supelco
L-Glutamine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium taurocholate hydrate, ≥97.0% (TLC)
Sigma-Aldrich
L-Glutamine, Vetec, reagent grade, ≥99%